title: Charles River Sprague Dawley rats lack early age-dependent susceptibility to DMBA-induced mammary carcinogenesis.
abstract: Developmental stages of mammary glands influence their susceptibility to initiating events related to carcinogenesis. The "window of susceptibility" to mammary carcinogenesis is classically defined as the time in early puberty when the mammary gland morphology is most sensitive to initiation events. Administration of the polyaromatic hydrocarbon, 7,12-dimethylbenz(a)anthracene (DMBA), in a single oral dose yields maximal mammary tumor formation when administered in this "window". We examined the DMBA treated mammary glands, precursor lesions, and morphology of the uninvolved mammary epithelium for the first 100 days of life for Charles River Sprague Dawley CD(R) IGS. Our goal was to determine the DMBA dose at which 50% of the rats (IC50) developed carcinoma in situ (CIS) within three months of dosing. Here we demonstrate, rather than the classical U-shaped dose curve in which there is maximum sensitivity for DMBA at 50 days, there is an increasing degree of sensitivity with age in the CD(R) IGS rat. Additionally, we report that vehicle-treated animals developed mammary CIS without any known initiator, and 100 day virgin animals demonstrated lactational changes, independent of DMBA exposure or dose. Lastly, we demonstrate this strain of virgin female rats has elevated pituitary prolactin immunoreactivity independent of the level of mammary differentiation. We conclude this strain of Charles River Sprague Dawley rats has prolactin-induced pituitary stimulation, and therefore, the window of susceptibility for mammary tumorigenesis is absent.
authors.affiliation: Department of Psychiatry, University of Cincinnati, PO Box 670559, Cincinnati, OH 45267-0559, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Gear
authors.forename: M
authors.initials: M
authors.lastname: Yan
authors.forename: J
authors.initials: J
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Succop
authors.forename: S C
authors.initials: SC
authors.lastname: Heffelfinger
authors.forename: D J
authors.initials: DJ
authors.lastname: Clegg
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000008:administration & dosage; D000236:Adenoma / Q000473:pathology; D000367:Age Factors; D000818:Animals; D015197:Carcinogenicity Tests; D002277:Carcinoma / Q000473:pathology; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D005260:Female; D006965:Hyperplasia; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced*; D010902:Pituitary Gland / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D015127:9,10-Dimethyl-1,2-benzanthracene